FGP
MIRM icon

Freestone Grove Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Freestone Grove Partners’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,692
Closed -$450K – 1109
2025
Q4 		$450K Buy
+5,692
New +$409K ﹤0.01% 590

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Freestone Grove Partners's MIRM Position: Q1 2026 in Review

Freestone Grove Partners sold out of Mirum Pharmaceuticals (MIRM) in Q1 2026, closing a stake of 5,692 shares — an estimated $450K sold.

Freestone Grove Partners first reported a position in MIRM in Q4 2025 and held it in 1 quarter. The position peaked at $450K in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Freestone Grove Partners reported no remaining Mirum Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 5,692 Mirum Pharmaceuticals shares in Q1 2026, an estimated $450K.
  • Freestone Grove Partners first reported a position in Mirum Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Mirum Pharmaceuticals position peaked at $450K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.